Impact of Early, Low-Dose Factor VIIa on Subsequent Transfusions and Length of Stay in Cardiac Surgery

•Recombinant Factor VIIa (rFVIIa) has been used for cardiac surgical bleeding in an off-label manner•Previous studies have identified that low dose rFVIIa (<40 mcg/kg) may have less thrombotic potential than the higher approved doses for hemophilia (90 mcg/kg)•The optimal timing of when to administer rFVIIa during the course of cardiac surgical bleeding resuscitation is unknown•The current analyzed timing of administration of low dose rFVIIa in terms of number of allogeneic transfusions and found unclear benefit without increased adverse events